Core Insights - Sakyproral has launched a new at-home teeth whitening routine that includes the G5Smart Electric Toothbrush, ULTRA WHITE Purple Toothpaste, and TRIPLE Purple Whitening Strips, focusing on ease of use and daily maintenance [2][11] Product Overview - **G5Smart Electric Toothbrush**: This toothbrush features guided brushing with real-time visual feedback via an LED display, tracking brushing angle and movement without the need for an app. It includes a built-in timer, six brushing modes, and color-fading bristles to indicate when to replace the brush head [5][6] - **ULTRA WHITE Purple Toothpaste**: A peroxide-free toothpaste that utilizes purple color correction and a dual-enzyme blend to enhance daily brightness, showing noticeable results in just three days [8][9] - **TRIPLE Whitening Strips**: These strips are designed for fast-acting whitening, providing visible results in 30 minutes and up to four shades whiter in seven days, while balancing speed and comfort [11][12] Market Positioning - Sakyproral aims to simplify oral care routines, encouraging consumers to adopt better habits for maintaining oral health. The brand emphasizes the importance of daily maintenance over single in-office treatments for lasting results [11][13] Pricing Information - G5Smart Electric Toothbrush: MSRP $39.99 [12] - ULTRA WHITE Purple Toothpaste (3.88 oz, Pack of 1): MSRP $9.99 [12] - ULTRA WHITE Purple Toothpaste (3.88 oz, Pack of 2): MSRP $17.99 [12] - TRIPLE Whitening Strips: MSRP $29.99 [12]

Core Insights - NKGen Biotech's troculeucel shows promising cognitive benefits in moderate Alzheimer's patients, with 100% of patients stable or improved and 50% improving from moderate to mild cognitive function [1][4][7] Clinical Data - Pooled analyses from two Phase 1 trials indicate that 92% of patients exhibited stable or improved cognitive function, with dose-responsive trends observed [3][5] - At the three-month assessment, all patients demonstrated stability or improvement across multiple cognitive measures, with higher doses (1 to 6 billion cells) correlating with greater benefits [5][6] - Early signs of durability were noted in patients followed for up to 12 months, with improvements maintained throughout treatment [8] Safety Profile - Troculeucel was well-tolerated, with no treatment-related adverse events reported in the Phase 1 studies [9] Biomarker Correlations - Exploratory plasma GFAP analyses showed strong correlations with clinical measures of disease severity, reinforcing its potential as a non-invasive biomarker for Alzheimer's [10][14] - Baseline plasma GFAP levels correlated significantly with cognitive status, and these correlations remained robust following treatment [14]

Core Perspective - The joint venture between Core AI Holdings and Toto Digital & Technology Solutions aims to leverage the increasing demand for AI-driven data center capacity, focusing on high-performance computing and AI workloads [1][2][4] Joint Venture Details - The partnership establishes a scalable platform for developing and operating advanced data center campuses specifically designed for AI and HPC workloads, addressing the growing global demand for compute capacity [2][4] - Toto DTS contributes significant operational expertise, having delivered 253 data centers and over 4.5 gigawatts of installed IT capacity across various complex environments [3] Strategic Importance - Core AI's CEO emphasizes that this joint venture positions the company at the forefront of a major infrastructure supercycle, driven by the unprecedented demand for power-dense computing environments [4] - The collaboration aims to create a scalable, energy-integrated data center platform tailored for AI, with the potential to generate substantial long-term shareholder value [4] Operational Focus - The joint venture will prioritize energy-optimized data center campuses that meet the performance, efficiency, and sustainability needs of AI and HPC customers, targeting key domestic markets [4][5]

Core Insights - OwlTing Group has been recognized for its significant growth, achieving a 42% Compound Annual Growth Rate (CAGR) from 2021 to 2024, with an absolute revenue growth of 189%, surpassing the entry threshold of 8.4% for the Financial Times' "High-Growth Companies Asia-Pacific 2026" list, where it ranked No. 226 among the top 500 fastest-growing companies in the region [4][3]. Company Performance - The ranking reflects OwlTing's operational durability and scale across its core business lines, indicating a strong foundation for future growth [4]. - The company has built a compliant digital currency payment infrastructure aimed at facilitating efficient and safe cross-border transactions for global enterprises and consumers [5][6]. Strategic Collaborations - OwlTing is collaborating with leading payment networks, including Circle Payments Network and Visa, to enhance its payment infrastructure, enabling near-instant digital currency transactions and connecting to over 11 billion endpoints globally [5][6]. Operational Efficiency - The deployment of OwlPay with Hope for Haiti resulted in a 93% reduction in international transfer costs and near-instant settlement, showcasing the effectiveness of its payment solution compared to traditional banking methods [6]. Regulatory Compliance - The company operates with a compliance-first foundation across multiple jurisdictions, including the United States, the European Union, and Japan, which is seen as a competitive advantage in the digital currency settlement space [6]. Industry Position - OwlTing was ranked among the top 2 global players in the "Enterprise & B2B" category within the digital currency sector, highlighting its significant role in the evolving fintech landscape [8].

Core Insights - MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer effective March 30, 2026, succeeding Douglas Swirsky [1] - Ahuja brings over 20 years of finance leadership experience, particularly in the life sciences sector, having previously served as Vice President of Investor Relations at Agilent Technologies [2] - Ahuja expressed enthusiasm about joining MaxCyte, highlighting the transformative potential of the company's electroporation platform for the Cell and Gene Therapy industry [3] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3] - The company utilizes its Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3] - MaxCyte has over 25 years of experience in cell engineering, contributing to the future of medicine [3]

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose rel ...

Core Insights - Kaltura has formed a strategic partnership with Cornerstone OnDemand to enhance AI-powered video learning experiences within Cornerstone's workforce agility ecosystem [1][2][3] Group 1: Partnership Overview - The partnership aims to address the growing demand for personalized and impactful training programs as businesses adapt to the AI era [2] - Kaltura's AI-driven video technology will be integrated into Cornerstone Galaxy, enhancing workplace training and career development opportunities [3][4] Group 2: Benefits of Integration - The integration will allow enterprises to deliver engaging video learning experiences that improve workforce growth, productivity, and skill development [4] - Kaltura's capabilities will support the creation of customized learning paths, automated content creation, and interactive video experiences [3][5] Group 3: Statements from Leadership - Kaltura's General Manager emphasized the importance of dynamic and accessible learning experiences for modern organizations [5] - Cornerstone's Group VP highlighted the significance of hyper-personalized digital content in developing talent and enhancing customer learning experiences [5] Group 4: Company Backgrounds - Kaltura focuses on providing rich digital experiences through intelligent content creation and management, serving various sectors including education and finance [6] - Cornerstone's Galaxy platform supports organizations in identifying skills gaps and providing diverse learning experiences, with a user base of approximately 140 million across 180+ countries [7]

Core Insights - FOREWARN, LLC has partnered with the Buffalo Niagara Association of REALTORS® (BNAR) to provide its services to over 3,600 real estate professionals in Western New York, focusing on enhancing agent safety [1][3]. Service Overview - FOREWARN offers a platform that analyzes billions of data points to help real estate agents mitigate risks by verifying identities, searching criminal histories, and validating client information using just a phone number [2]. - The services provided by FOREWARN to BNAR members are available at no additional cost [2]. Executive Statement - John Leonardi, CEO of BNAR, emphasized the importance of equipping members with tools for success while ensuring their safety in a changing environment, highlighting the real-time insights provided by FOREWARN [3]. Additional Information - Other real estate agencies and professionals can learn more about FOREWARN through their website [4]. - FOREWARN aims to enhance safety and facilitate smarter interactions by leveraging powerful analytics and a vast data repository [5].

Core Viewpoint - Humacyte, Inc. is set to release its financial results for the quarter and year ended December 31, 2025, on March 27, 2026, and will provide a corporate and financial update during a conference call [1][2]. Company Overview - Humacyte, Inc. is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at a commercial scale [1][3]. - The company manufactures acellular tissues aimed at treating various diseases, injuries, and chronic conditions [3]. - Humacyte's Biologics License Application for its acellular tissue engineered vessel (ATEV), named Symvess, was approved by the FDA in December 2024 for vascular trauma [3]. - The ATEV is currently undergoing late-stage clinical trials for additional vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [3]. - The company is preparing for human clinical studies in coronary artery bypass graft surgery and is also in preclinical development for conditions such as type 1 diabetes and pediatric heart disease [3]. - Humacyte's 6mm ATEV for AV access in hemodialysis was the first to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received Fast Track designation [3]. Upcoming Events - The financial results and corporate update will be presented during a conference call scheduled for March 27, 2026, at 8:00 a.m. Eastern Time [2]. - Investors can join the call using specific contact numbers provided for U.S. and international participants [2].

Core Viewpoint - Oryzon Genomics has received a significant U.S. patent for iadademstat, a selective LSD1 inhibitor, which strengthens its position in the oncology market, particularly for treating acute myeloid leukemia (AML) in combination with existing therapies like venetoclax [1][5]. Patent Details - The U.S. patent US12,564,559 B2 covers therapeutic combinations of iadademstat for treating neoplastic diseases, including AML, and is set to expire in January 2039, with potential for further extensions [2][3]. - The patent includes claims for combinations with venetoclax, which is a standard treatment for first-line AML, enhancing the long-term value of Oryzon's clinical programs [5]. Clinical Development - Iadademstat is currently being evaluated in seven ongoing oncology clinical trials, including the Phase Ib ALICE-2 study, which has shown a 100% overall response rate (ORR) and a 90% strict complete remission (CR) rate in preliminary data [4][8]. - Updated data from approximately 15-16 patients in the ALICE-2 study are expected to be presented at the European Hematology Association Annual Congress in June 2026 [4]. Intellectual Property Portfolio - In addition to the U.S. patent, Oryzon has secured patent protection for iadademstat combinations in multiple countries, including Australia, Brazil, Canada, Europe, India, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, and Russia, with additional applications pending [5]. - Oryzon also holds patents for iadademstat combinations with other AML therapies, such as azacitidine and decitabine, in the U.S. and other jurisdictions [5]. Company Overview - Founded in 2000 and headquartered in Barcelona, Spain, Oryzon is a clinical-stage biopharmaceutical company focused on epigenetics and personalized medicine for CNS disorders and oncology [6]. - The company has a robust clinical portfolio centered around two LSD1 inhibitors: iadademstat for oncology and vafidemstat for CNS disorders, with ongoing Phase I and II studies [6]. Mechanism of Action - Iadademstat is a small oral molecule that selectively inhibits the epigenetic enzyme LSD1, demonstrating significant potential in hematologic cancers [7]. - The drug has shown promising safety and clinical activity in combination therapies, including trials for relapsed/refractory AML and other hematological conditions [9].